Drug interactions
Cenobamate + Empagliflozin-linagliptin
Severity: Minor
Cenobamate and Empagliflozin-linagliptin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Cenobamate can induce CYP3A4 and may lower linagliptin exposure. Linagliptin is only partly metabolized by CYP3A4, so glycemic control could be slightly weaker. The effect is generally modest.
What this interaction means in plain words
Cenobamate and Empagliflozin-linagliptin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Cenobamate belongs to Central Nervous System; Empagliflozin-linagliptin belongs to Endocrine.
Why it happens
Weak to moderate CYP3A4 induction by cenobamate, possibly with P-gp effects, increases linagliptin clearance.
What to do
Monitor glucose and HbA1c after cenobamate is started or stopped. Intensify antidiabetic therapy if control worsens.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Cenobamate and Empagliflozin-linagliptin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Empagliflozin-linagliptin
Other interactions of Cenobamate
Frequently asked questions
Can I take Cenobamate with Empagliflozin-linagliptin?
MediHelp rates the interaction as minor. Cenobamate and Empagliflozin-linagliptin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Cenobamate can induce CYP3A4 and may lower linagliptin exposure. Linagliptin is only partly metabolized by CYP3A4, so glycemic control could be slightly weaker. The effect is generally modest.
How serious is the interaction between Cenobamate and Empagliflozin-linagliptin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor glucose and HbA1c after cenobamate is started or stopped. Intensify antidiabetic therapy if control worsens.
What other medicines interact with Empagliflozin-linagliptin?
MediHelp also lists interactions of Empagliflozin-linagliptin with, for example, Fosphenytoin, Rifampin, Rifapentine. The full list is on the Empagliflozin-linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
